Log in


  • Home
  • IP Legal Considerations for Precision Medicine and Digital Health Companies

Donation goal

0%
Goal:
$500.00
Collected:
$0.00

IP Legal Considerations for Precision Medicine and Digital Health Companies

  • Fri, March 19, 2021
  • 09:00 - 10:00

Registration is closed

Fri, March 19, 2021, 09:00 – 10:00AM (PDT), 12:00 – 1:00PM (EST)


Abstract


Provide an introduction to the Haynes and Boon Precision Medicine and Digital Health IP Group and our capabilities. Discussion of the more pertinent IP issues relating to precision medicine and digital health (PMDH), such as: securing and protecting data rights in technology transactions, patentability issues with PMDH inventions, the interplay between trade secret and patent protection with respect to PMDH inventions, and how COVID-19 has impacted how companies secure and manage their IP rights.


2021 International Comparative Legal Guide – Digital health (https://iclg.com/practice-areas/digital-health-laws-and-regulations)


Haynes and Boone’s Precision Medicine and Digital Health lawyers provide full-service counsel to the key players in precision medicine and digital health – from technology startups to established corporations, health insurers, pharmaceuticals, and investors supporting the industry. The team draws on the firm’s highly regarded healthcare, life sciences, technology and intellectual property experience to address trends in evolving markets, cutting-edge advances in technology, and legal and regulatory changes.



Speaker:

Jason Novak and Roger Kuan 


Roger Kuan

Roger Kuan is a Partner at Haynes and Boone and chair of the Precision Medicine and Digital Health Practice Group, where he counsels companies that are uniquely positioned in the convergence of the life/medical sciences and technology industries on how to successfully navigate the complexities of the intellectual property (IP), data rights and regulatory challenges they encounter.

Roger has extensive experience in IP strategy and portfolio management (utility/design patents, trademarks, copyrights, and trade dress), data rights strategy, licensing and technology transactions, freedom-to-operate clearances, enforcement, monetization, IP due diligence, and dispute resolution. His practice is focused in the life sciences sector with an emphasis in emerging technologies such as Precision Medicine, Digital Health and 3D printing/bioprinting.

Prior to joining Haynes and Boone, Roger served as Director, IP Counsel at a multinational biotechnology company. Prior to finishing his law degree, he worked in the life sciences industry for several Fortune 500 pharmaceutical, medical device, and chemical companies.

Jason Novak

Jason Novak is a Partner in Haynes and Boone’s Precision Medicine and Digital Health Practice Group, where he focuses on advising entities on the various legal issues that can arise with emerging technologies in the healthcare and life sciences industries.

Jason has extensive experience in IP strategy and patent portfolio management, preparation and prosecution, oppositions, counseling, licensing and technology transactions, in and out-licensing, freedom-to-operate, various types of due diligence, IP training, risk recognition and management, and dispute resolution. He directs that experience to clients in various industries, particularly in the medical device, personalized/precision medicine, digital health, life sciences tooling, and food industries.

Prior to starting this practice, Jason was a IP Director for Thermo Fisher Scientific, where he managed worldwide IP needs in genetic sciences instrumentation and software. Before moving into the legal industry, Jason was a research engineer for a leading food product company, where he led numerous product and process redesigns, reformulations and launches.



Strategic Alliance:


文本转语音功能仅限200个字符
选项 : 历史 : 反馈 : Donate 关闭



@Dahshu 2020

文本转语音功能仅限200个字符
选项 : 历史 : 反馈 : Donate 关闭
G
M
T
Y
文本转语音功能仅限200个字符
Powered by Wild Apricot Membership Software